Japan approves VYVGART (efgartigimod alfa) for intravenous use in adults with primary immune thrombocytopenia (ITP).
Argenx SE announces approval of VYVGART (efgartigimod alfa) by Japan's Ministry of Health, Labour and Welfare for intravenous use in adults with primary immune thrombocytopenia (ITP). VYVGART received global approval in ITP after meeting the primary endpoint of the global Phase 3 ADVANCE-IV trial, demonstrating a higher proportion of chronic ITP patients achieved a sustained platelet count response compared to placebo. Common side effects include respiratory tract infection, headache, and urinary tract infection.
March 26, 2024
8 Articles